BRCA1 and breast carcinoma: Recently, the EMBRACA and the OlympiaD trials have demonstrated that PARP inhibitor treatment using olaparib or talazoparib improves progression-free survival as compared to standard chemotherapy in advanced breast cancer patients that harbor a germline BRCA1 or BRCA2 mutation [16, 17].